Navigation Links
Baylor Heart and Vascular Hospital Announces First Patient Procedure in the United States to Treat Atrial Fibrillation Using New Catheter for Cryoablation Technology
Date:5/2/2011

DALLAS, May 2, 2011 /PRNewswire-USNewswire/ -- Baylor Jack and Jane Hamilton Heart and Vascular Hospital today announced the first patient procedure in the U.S. using the Achieve™ Mapping Catheter, an intra-cardiac electrophysiology diagnostic catheter that can be used to assess pulmonary vein isolation when treating paroxysmal atrial fibrillation (PAF). Atrial fibrillation is the most common and one of the most undertreated heart rhythm disorders. The procedure was performed last week by an electrophysiologist on the medical staff at Baylor Heart and Vascular Hospital in Dallas.

The new catheter technology is approved by the U.S. Food and Drug Administration for use with Medtronic's Arctic Front® Cardiac CryoAblation Catheter System to provide a more straightforward treatment approach. When used in conjunction with Arctic Front, the Achieve Mapping Catheter combines pulmonary vein diagnostic and ablation capabilities in a single system. The Achieve Mapping Catheter is deployed through the Arctic Front guide wire lumen enabling the Arctic Front procedure to be performed using a single transseptal puncture with minimal catheter exchanges, enabling physicians to map electrical conduction between the left atrium and pulmonary veins in order to assess pulmonary vein potentials before, during and after cryoablation.

"In many cases, this new mapping catheter will allow real-time assessment for PV isolation and provide valuable information regarding time-to-effect during the cryoablation procedure," said Dr. Robert Kowal, M.D., Ph. D., an electrophysiologist on the medical staff at BHVH. "The procedure can be completed more efficiently by incorporating this new technology."

The Arctic Front Cardiac CryoAblation Catheter, approved by the FDA in December 2010, is the first and only cryoballoon in the United States indicated for the treatment of PAF. Baylor Heart and Vascular Hospital was the first in North Texas to offer the Arctic Front CryoAblation Catheter and was a major participant in the STOP-AF trial which demonstrated its effectiveness.  The cryoablation treatment involves a minimally-invasive procedure that creates circumferential lesions around the pulmonary vein (the source of erratic electrical signals that cause atrial fibrillation) and blocks the conduction of atrial fibrillation in cardiac tissue through the use of a coolant.

ABOUT BAYLOR HAMILTON HEART AND VASCULAR HOSPITAL:

Baylor Jack and Jane Hamilton Heart and Vascular Hospital (Baylor Hamilton) was the first hospital in North Texas dedicated solely to the care and treatment of patients with cardiovascular disease. The 64-bed Baylor Hamilton was recognized in 2009 and again in 2010 for having the nation's lowest readmission rate for heart failure patients for the second consecutive year and continues to receive a five star rating by HealthGrades, a leading independent health care rating organization. At BHVH, more than 600 procedures to treat atrial fibrillation are performed annually.  For more information about Baylor Hamilton Heart and Vascular Hospital, visit BaylorHeartHospital.com.

Physicians are members of the medical staff at one of Baylor Health Care System's subsidiary, community or affiliated medical centers and are neither employees nor agents of those medical centers, Baylor University Medical Center at Dallas or Baylor Health Care System.


'/>"/>
SOURCE Baylor Jack and Jane Hamilton Heart and Vascular Hospital
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Baylor Adds Naviscan PEM Technology to Womens Imaging Center
2. Baylor Health Care System Registers its Commitment to Achieve Meaningful Use of the Electronic Health Record
3. Baylor Hamilton Heart Hospital Implants First MRI-Safe Pacemaker in North Texas
4. Many Heart Attack Patients Dont Get Best Emergency Treatment
5. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
6. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
7. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
8. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
9. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
10. Its Only Heartburn...or is it? Chronic Heartburn a Risk Factor for Precursor to Esophageal Cancer
11. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 19, 2017 Global Prostate Cancer Therapeutics ... the prostate cancer therapeutics market analyzes the current ... prevalence of prostate cancer, launch of promising emerging ... of new drugs & therapeutic biological products, and ... to lesser side effects are some of the ...
(Date:4/19/2017)... The Global Effective Microorganisms (EM) Market by Manufacturers, ... and analysed the potential of Global Effective Microorganisms (EM) Market ... growth factors. The report identifies and analyses the emerging trends ... market. ... and Figures, 6 Major Company Profiles, spread across 124 pages ...
(Date:4/19/2017)... Companion animal vaccines ... pets such as canine, avian and feline. ... such as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated ... Recombinant Vaccines. Attenuated live vaccines are derived from ... have been weakend under laboratory conditions. Conjugate vaccines ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... Somnoware, a leading provider ... Online(TM), which enables sleep physicians to create and edit their interpretation reports. This ... provides a familiar interface that does not require additional training to use. It ...
(Date:4/28/2017)... NY (PRWEB) , ... April 28, 2017 , ... ... Laboratory to expanded distribution of the GlycoMark test throughout the Northeast U.S. ... hyperglycemia in patients with diabetes. The GlycoMark test provides a clinically proven one- ...
(Date:4/28/2017)... york (PRWEB) , ... April 28, 2017 , ... ... to announce that Aditya Patel M.D. has joined the revolutionary endoscopic practice under ... and board certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt Technique created ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection and ... drug safety and minimize the cost of development. In this webinar, sponsored by ... cell lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). , ...
(Date:4/28/2017)... ... April 28, 2017 , ... Researchers at ... ActiGraph’s CentrePoint Data Hub in a sample of participants enrolled in ... activity and sleep monitoring solutions for the global scientific community. The company’s new ...
Breaking Medicine News(10 mins):